Journal article
Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States
HPB (Oxford, England), Vol.24(10), pp.1729-1737
10/01/2022
DOI: 10.1016/j.hpb.2022.05.003
PMID: 35717430
Abstract
Background: Exocrine pancreatic insufficiency (EPI) is frequently seen in patients with pancreatic cancer (PDAC) and is thought to contribute to nutritional complications. While EPI can be pharmacologically temporized with pancreatic enzyme replacement therapy (PERT), there is lack of clear evidence informing its use in PDAC. Here we aim to survey pancreatic surgeons regarding their utilization of PERT in the management of EPI for PDAC. Methods: An online survey was distributed to the members of The Americas Hepato-Pancreato-Biliary Association (AHPBA) and The Pancreas Club. Results: 86.5% (180/208) of surgeons prescribe PERT for at least some resectable/borderline resectable PDAC cases. Only a minority of surgeons order investigations to confirm EPI before starting PERT (28.1%) or test for adequacy of therapy (28.3%). Few surgeons believe that PERT has an effect on overall survival (19.7%) or disease-free survival (6.25%) in PDAC. Conclusion: PERT is widely prescribed in patients with resectable/borderline resectable PDAC, but investigations establishing EPI and assessing PERT adequacy are underutilized. A substantial proportion of surgeons are unclear as to the effect of PERT on survival outcomes in PDAC. These data call for prospective studies to establish guidelines for optimal use of PERT and its effects on survival outcomes in PDAC.
Details
- Title: Subtitle
- Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States
- Creators
- Tejeshwar Jain - University of Alabama at BirminghamPrateek Sharma - University of Alabama at BirminghamBhuwan Giri - University of MiamiSrikanth Iyer - University of Alabama at BirminghamVrishketan Sethi - University of Alabama at BirminghamEjas P. Bava - University of Alabama at BirminghamUtpreksha Vaish - University of Alabama at BirminghamPreeti Sahay - University of Alabama at BirminghamJashodeep Datta - University of MiamiSushanth Reddy - University of Alabama at BirminghamJohn Bart Rose - Division of Surgical Oncology at Department of Surgery, O'Neal Comprehensive Cancer Centre, UAB, Birmingham, AL, United StatesAnam Khan - The University of Texas MD Anderson Cancer CenterNipun Merchant - University of MiamiSuresh T. Chari - The University of Texas MD Anderson Cancer CenterVikas Dudeja - University of Alabama at Birmingham
- Resource Type
- Journal article
- Publication Details
- HPB (Oxford, England), Vol.24(10), pp.1729-1737
- DOI
- 10.1016/j.hpb.2022.05.003
- PMID
- 35717430
- NLM abbreviation
- HPB (Oxford)
- ISSN
- 1365-182X
- eISSN
- 1477-2574
- Number of pages
- 9
- Grant note
- R01 DK 111834 / National Institutes of Health (100000002) W81XWH-16-1-0570 / U.S. Department of Defense (100000005) W81XWH-16-1-0570; W81XWH-17-1-0392 / U.S. Department of Defense (http://data.elsevier.com/vocabulary/SciValFunders/100000005) National Institutes of Health (http://data.elsevier.com/vocabulary/SciValFunders/100000002) U.S. Department of Defense (http://data.elsevier.com/vocabulary/SciValFunders/100000005) R01DK111834 / National Institute of Diabetes and Digestive and Kidney Diseases (http://data.elsevier.com/vocabulary/SciValFunders/100000062) National Institute of Diabetes and Digestive and Kidney Diseases (http://data.elsevier.com/vocabulary/SciValFunders/100000062) W81XWH-17-1-0392 / U.S. Department of Defense (100000005)
- Language
- English
- Date published
- 10/01/2022
- Academic Unit
- Anatomy and Cell Biology; Surgery
- Record Identifier
- 9985244582502771
Metrics
1 Record Views